莲必治注射液联合头孢曲松钠他唑巴坦钠治疗老年肺炎的临床研究

Clinical study on Lianbizhi Injection combined with ceftriaxone sodium and tazobactam sodium in treatment of senile pneumonia

目的探讨莲必治注射液联合头孢曲松钠他唑巴坦钠治疗老年肺炎患者的有效性和安全性。方法选取2016年1月—2017年12月石家庄市第三医院收治的老年肺炎患者110例,随机分成对照组和治疗组,每组各55例。对照组静脉滴注注射用头孢曲松钠他唑巴坦钠,3 g加入250 mL生理盐水,2次/d;治疗组在对照组基础上静脉滴注莲必治注射液,10 mL加入250m L生理盐水,2次/d。两组患者均连续治疗14d。观察两组患者临床疗效,同时比较治疗前后两组患者临床体征消失时间和血清学指标。结果治疗后,对照组和治疗组临床有效率分别为80.00%和94.55%,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组患者咳嗽消失时间、退热时间、肺啰音消失时间及X线胸片炎症完全吸收时间均要显著早短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清C-反应蛋白(CRP)、可溶性髓样细胞触发受体-1(sTREM-1)和脑钠肽(BNP)水平显著降低(P<0.05),且治疗组患者CRP、sTREM-1和BNP水平较对照组降低更明显,两组比较差异具有统计学意义(P<0.05)。结论莲必治注射液联合头孢曲松钠他唑巴坦钠治疗老年肺炎疗效好、安全性高,可显著改善患者血清学生化指标,具有一定的临床推广应用价值。

Objective To investigate the efficacy and safety of Lianbizhi Injection combined with ceftriaxone sodium and tazobactam sodium in treatment of senile pneumonia. Methods Patients（110 cases） with pneumonia in Shijiazhuang Third Hospital from January 2016 to December 2017 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were iv administered with Lianbizhi Injection, 3 g added into normal saline 250 mL, twice daily. Patients in the treatment group were iv administered with Ceftriaxone Sodium and Tazobactam Sodium for injection on the basis of the control group, 10 mL added into normal saline 250 mL, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical signs, the serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.00% and 94.55%, respectively, and there were differences between two groups（P〈0.05）. After treatment, the disappearance times of cough, fever and lung rale, and the complete absorption time of inflammation of X-ray chest in the treatment group were significantly earlier than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the CRP, sTREM-1, and BNP levels in two groups were significantly decreased（P〈0.05）, and the CRP, sTREM-1, and BNP levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups（P〈0.05）. Conclusion Lianbizhi Injection combined with ceftriaxone sodium and tazobactam sodium in treatment of senile pneumonia has high curative effect and safe, can significantly improve the serological indicators, which has a certain clinical application value.